May 21, 2010 – A new stent delivery system is designed to be reliable, easy to use and precise when delivering the self-expanding Supera peripheral vascular stent. The new delivery system was launched this week in Europe.
The Supera Veritas system was developed to deliver the Supera for the treatment of biliary and peripheral artery disease (PAD).
“We have been utilizing the Supera stent clinically for more than two years and we are very impressed with the performance of the stent and positive clinical outcomes,” said Dierk Scheinert, M.D., chairman of the Center for Vascular Medicine at the Park Hospital Leipzig, Germany. "With the new Supera Vertas delivery system, we now have a more effective tool for the smooth and controlled deployment of the Supera stent. It significantly reduces the number of steps needed to prep and deliver the stent, all of which greatly increase its ease of use and accuracy.”
The IDEV Inc. expects to introduce two additional products in its family of Supera stents by the end of this year. The stent uses an interwoven self-expanding nitinol design. It has U.S. Food and Drug Administration (FDA) 510(k) clearance for palliative treatment for biliary strictures produced by malignant neoplasms. It is currently the focus of a prospective, FDA-approved, single-arm clinical trial of 258 patients at up to 40 sites in the United States.
For more information: www.idevtechnologies.com
October 16, 2024 
